Skip to main content
  • Length of surgery:

    30-60 min

  • Anaesthetic:

    General Anaesthetic

  • Hospital stay :

    1 night (In-patient)

  • Time off work :

    1 week

  • Time off exercise:

    6 weeks

  • Time to fully settle :

    n/a

  • Post-op care:

    Clinic review to discuss findings and further treatment plan.


This procedure involves the surgical insertion of a suprapubic catheter (SPC) into the bladder through the lower abdominal wall to establish urinary drainage. It is typically performed under general anaesthetic, using both ultrasound and endoscopic guidance.

Where indicated, a diagnostic cystoscopy ± urethral dilatation is first performed to assess the urethra and bladder, and to confirm safe intravesical access. A cystostomy tract is then created percutaneously under direct vision and ultrasound guidance, and the SPC is inserted and secured in place.

Indications include:

  • Urethral trauma or obstruction

  • Failed or traumatic transurethral catheterisation

  • Neurogenic bladder dysfunction requiring long-term SPC

  • Bladder outlet obstruction unsuitable for urethral catheterisation

  • Definitive management of BPH or urethral stricture disease

The suprapubic approach avoids the urethra and is often preferred for long-term bladder drainage, particularly in patients at risk of urethral trauma or with poor tolerance of transurethral catheters.

Follow-up considerations:

  • Routine catheter care, with SPC changes every 2 months, or monthly in cases of recurrent urinary tract infections (UTIs)

  • Monitoring for complications such as infection, encrustation, and catheter dislodgement

  • Assessment of long-term bladder function as appropriate. Daytime use of a flip-flow valve is advisable to preserve bladder capacity.

UTI prophylaxis may include:

  • D-mannose 1g twice daily

  • Adequate fluid intake (minimum 2 litres/day)

  • Timely catheter changes based on individual risk

  • Further investigation (e.g., ultrasound, cystoscopy) to exclude bladder stones if UTIs persist

  • Uromune® immunotherapy may be considered for selected patients with recurrent UTIs